Sanofi Shares Drop 2.5% Breaking Through the €72.72 Support Level
The pharmaceutical company significantly declines mid-morning and is among the worst performers on the CAC 40. The stock breaks through a closely watched technical threshold in a downward trending Parisian market.
A Retreat that Erases the Gains Made Last Friday on the CAC 40
Sanofi shares fell 2.62% to €72.20 at mid-session, among the steepest declines on the CAC 40, while the Paris index itself dropped 0.72%. This decline substantially erases the rebound from last Friday, when the stock had gained more than 2.5% and was among the leaders of the index. Over the week, the stock is down 5.73%, and 6.89% over the month.
The day's news includes the appointment of Paulo Fontoura as the new Executive Vice President in charge of Global Pharma R&D, replacing Houman Ashrafian. The new appointee, a former Roche executive, will take up his role on September 1, 2026, and will join the executive committee. This downward movement also occurs in an unfavorable sectoral context, with Hermès, EssilorLuxottica, and Publicis also in the red.
€72.72 Support Level Breached During the Session, Technical Configuration Deteriorated
During the session, the stock breached its technical support level of €72.72, identified as a reference threshold, and is now trading below it. The price remains significantly distant from its three moving averages: 4.66% below the MM20 (€75.73), 6.03% below the MM50 (€76.83), and nearly 10.7% below the MM200 (€80.83), indicating a bearish orientation established over the medium term. The RSI at 43 remains in the neutral zone, which does not provide a signal of seller exhaustion at this stage.
According to the consensus of analysts surveyed, the stock is trading at approximately 8.5 times the earnings of the current fiscal year and 8 times those of the next fiscal year, based on an expected EPS growth of 5.9%. The stock is now trading below its €72.72 support level, after a cumulative decline of 7.19% over three months.
